Publications by authors named "Pierre Fustier"

Claim this Profile
T
The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study.
Jeff Kingsley, Nagalingeswaran Kumarasamy, Luis Abrishamian, Marc Bonten, Awawu Igbinadolor, Pierre Fustier

Open Forum Infect Dis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Clara Locher, Silvy Laporte, Peggy Derambure, Olivier Chassany, Cécile Girault, Pierre Fustier

Therapie· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data Monitoring Committees and clinical trials: From scientific justification to organisation.
Clara Locher, Silvy Laporte, Peggy Derambure, Olivier Chassany, Cécile Girault, Pierre Fustier

Therapie· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ensovibep, a SARS-CoV-2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first-in-human, ascending single-dose Phase 1 study.
Nina Stojcheva, Stacy Gladman, Marianne Soergel, Christof Zitt, Roxana Drake, Pierre Fustier

Br J Clin Pharmacol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.
Koji Izutsu, Yosuke Minami, Noriko Fukuhara, Yasuhito Terui, Tatsuro Jo, Pierre Fustier

Int J Hematol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
John P Leonard, Marek Trneny, Koji Izutsu, Nathan H Fowler, Xiaonan Hong, Pierre Fustier

J Clin Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Myron S Czuczman, Marek Trněný, Andrew Davies, Simon Rule, Kim M Linton, Pierre Fustier

Clin Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin, CCAAT/enhancer-binding proteins and lactate regulate the human 11β-hydroxysteroid dehydrogenase type 2 gene expression in colon cancer cell lines.
Thomas Andrieu, Pierre Fustier, Rasoul Alikhani-Koupaei, Irena D Ignatova, Andreas Guettinger

PLoS One· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).
Martin Früh, Richard Cathomas, Marco Siano, Gregor Tscherry, Alfred Zippelius, Pierre Fustier

Clin Lung Cancer· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of polymorphisms in the human 11beta-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity.
Rasoul Alikhani-Koupaei, Fatemeh Fouladkou, Pierre Fustier, Bruno Cenni, Arya M Sharma

FASEB J· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extracellular ATP determines 11beta-hydroxysteroid dehydrogenase type 2 activity via purinergic receptors.
Bert Kadereit, Pierre Fustier, Kushiar Shojaati, Brigitte M Frey, Felix J Frey

J Am Soc Nephrol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells.
Tusty-Jiuan Hsieh, Pierre Fustier, Chih-Chang Wei, Shao-Ling Zhang, Janos G Filep

J Endocrinol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines.
Ludovic Le Corre, Pierre Fustier, Nasséra Chalabi, Yves-Jean Bignon, Dominique Bernard-Gallon

Clin Chim Acta· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells.
Tusty-Jiuan Hsieh, Pierre Fustier, Shao-Ling Zhang, Janos G Filep, Shiow-Shih Tang

Endocrinology· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines.
Dominique J Bernard-Gallon, Cécile Vissac-Sabatier, David Antoine-Vincent, Pascale G Rio, Jean-Claude Maurizis, Pierre Fustier

Br J Nutr· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Presence of BRCA1 and BRCA2 proteins in human milk fat globules after delivery.
Cécile Vissac, Didier Lémery, Ludovic Le Corre, Pierre Fustier, Pierre Déchelotte

Biochim Biophys Acta· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis